

# BUSINESS

8D

 7D DIVIDENDS  
 7D FUTURES  
 7D MARKET  
 SUMMARY

DemocratandChronicle.com

WEDNESDAY, OCTOBER 11, 2006

## Area biotech lands deal on cancer drug

■ VirtualScopics to earn \$1.4M  
to help bring medicine to market.

**BEN RAND**  
STAFF WRITER

Another Rochester biotechnology firm is forging an agreement with a pharmaceutical manufacturer aimed at helping the company bring a new drug to market.

VirtualScopics Inc. announced today it has signed two 24-month contracts with MediciNova of San Diego for studies of the agent MN-029, which is potentially disruptive to certain cancers.

The contracts are valued at \$1.4 million.

VirtualScopics Inc. is a provider of advanced

medical image analysis services. The company evolved from research first carried out at the University of Rochester Medical Center and School of Engineering.

Announcement of the new contracts makes for a good day for Rochester's emerging biotechnology sector.

Vaccinex Inc., also a spin-off of UR, said today it has signed a licensing agreement with a French pharmaceutical targeting inflammatory disorders such as rheumatoid arthritis and certain cancers. □

BRAND@DemocratandChronicle.com